Login to Your Account

Other News To Note

Tuesday, January 8, 2013
• BioTime Inc., of Alameda, Calif., created subsidiary BioTime Acquisition Corp. (BAC), for an agreement with Geron Corp., of Menlo Park, Calif., to acquire Geron's human embryonic stem cell (hESC) program, including its Phase I hESC-derived oligodendrocytes for acute spinal cord injury and its autologous cellular immunotherapy program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription